MedPath

Adjuvant Radiotherapy in Patients With Early Endometrial Cancer

Not Applicable
Not yet recruiting
Conditions
Endometrial Cancer
Radiotherapy
Pathology
Interventions
Radiation: vaginal brachytherapy/pelvic external beam radiotherapy
Registration Number
NCT04956601
Lead Sponsor
Peking University Third Hospital
Brief Summary

To compare the effect of vaginal brachytherapy as adjuvant treatment after operation when compared to pelvic external beam radiotherapy in patients with early endometrial cancer based on moderate risk molecules classification.

Detailed Description

After being informed the study and potential risk,all patients giving written informed consent will be undergo a 1-week screening period determine eligibility for study entry. At week 0, patients who meet the eligibility will be randomized in a 1:1 ratio to vaginal brachytherapy or pelvic external beam radiotherapy. After treatment, patients were followed up regularly.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
480
Inclusion Criteria
  1. Endometrial adenocarcinoma is confirmed by pathology, and the molecular types were microsatellite instability type and low copy type;
  2. Stage IA and grade 3 or stage IB (FIGO 2009), without substantial lymph-vascular space invasion;
  3. Surgery must have included a hysterectomy and bilateral adnexectomy. Pelvic lymph node sampling and para-aortic lymph node sampling are optional;
  4. ECOG score is 0-2;
  5. The interval time between surgery and radiotherapy is no more than 8 weeks;
  6. The routine blood examination was normal;
  7. Compliance is good and informed consent is voluntarily signed.
Read More
Exclusion Criteria
  1. The patients receive chemotherapy;
  2. History of previous malignant disease;
  3. Previous diagnosis of Crohn's disease or ulcerative colitis.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
VBTvaginal brachytherapy/pelvic external beam radiotherapyCT image guided high-dose-rate vaginal brachytherapy, 30Gy/6f, 2f/w.
EBRTvaginal brachytherapy/pelvic external beam radiotherapyPelvic external beam radiotherapy,IMRT/VAMT,IGRT suggested,DT 45Gy/25f.
Primary Outcome Measures
NameTimeMethod
DFS5-year

disease-free survival from being received treatment

Secondary Outcome Measures
NameTimeMethod
Failure mode5-year

vaginal recurrences; pelvic recurrence; distant metastases

OS5-year

Overall survival from being received treatment

Toxicities5-year

from being received treatment

Trial Locations

Locations (1)

Peking University 3rd Hospital

🇨🇳

Beijing, Beijng, China

© Copyright 2025. All Rights Reserved by MedPath